Mabpharm Limited Share Price

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 01:38:27 30/09/2026 pm IST			5-day change	1st Jan Change
0.4500 ^HKD	-5.26%		+20.00%	-10.00%

28/08	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
24/06	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

394

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/26/30	HK$0.4500	-5.26%	56,000
29/26/29	HK$0.4750	-4.04%	0
28/26/28	HK$0.4950	-2.94%	0
25/26/25	HK$0.5100	+29.11%	16,000
24/26/24	HK$0.3950	+5.33%	46,000

Delayed Quote Hong Kong S.E.

More quotes

Market Cap	158.64Cr 185.43Cr 24Cr 21Cr 20Cr 18Cr 34Cr 2.28TCr 34Cr 237.48Cr 92Cr 1.16TCr 89Cr 87Cr 3.72TCr	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	180.39Cr 210.85Cr 27Cr 24Cr 22Cr 20Cr 38Cr 2.59TCr 39Cr 270.03Cr 104.53Cr 1.32TCr 100.89Cr 99Cr 4.23TCr	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

28/08	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
24/06	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
09/06	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
09/06	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
26/03	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
26/03	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
05/12	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/25/31	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/25/28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/25/27	Mabpharm Shrinks Loss by 39% in 2024	MT
26/25/26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/25/02	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI

13/23/13	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/21/20	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/21/30	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/21/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/21/12	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

1 day	-5.26%
1 week	+20.00%
1 month	+1.12%
3 months	+7.14%
6 months	-10.00%
Current year	-10.00%

1 week	0.4	0.54
1 month	0.35	0.54
Current year	0.31	0.81
1 year	0.31	0.81
3 years	0.25	0.94
5 years	0.25	1.2
10 years	0.25	1.8

Mabpharm Limited Share Price

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news: Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Price Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	28/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	01/12/2023
Jing Tao PRN	Corporate Officer/Principal	53	03/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	20/07/2018
Yun Feng Li BRD	Director/Board Member	49	20/07/2018
Shu Ge Jiao CHM	Chairman	60	20/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	-5.26%	+20.00%	-28.57%	-5.26%	24Cr
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	7.45TCr
ARGENX SE	-0.61%	+0.69%	+36.36%	+82.72%	6.01TCr
LONZA GROUP AG	-2.54%	-0.21%	+6.34%	+31.72%	4.82TCr
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	4.43TCr
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	4.4TCr
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	4.16TCr
CELLTRION, INC.	+3.32%	+3.49%	+11.18%	+51.23%	3TCr
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	2.93TCr
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	2.49TCr
Average	-0.57%	+3.21%	+46.91%	+138.32%	3.97TCr
Weighted average by Cap.	+0.17%	+1.22%	+59.94%	+145.69%

	2024	2025
Net sales	26Cr 30Cr 3.85Cr 3.42Cr 3.2Cr 2.91Cr 5.48Cr 370.37Cr 5.56Cr 39Cr 15Cr 188.63Cr 14Cr 14Cr 605.85Cr	65Cr 76Cr 9.62Cr 8.55Cr 7.99Cr 7.29Cr 14Cr 926.68Cr 14Cr 97Cr 37Cr 471.95Cr 36Cr 35Cr 1.52TCr
Net income	-13Cr -15Cr -1.91Cr -1.69Cr -1.58Cr -1.44Cr -2.72Cr -183.51Cr -2.75Cr -19Cr -7.41Cr -93Cr -7.16Cr -7Cr -300.19Cr	5.71Cr 6.68Cr 85.11L 75.6L 70.69L 64.42L 1.21Cr 82Cr 1.23Cr 8.55Cr 3.31Cr 42Cr 3.2Cr 3.13Cr 134.04Cr
Net Debt	22Cr 26Cr 3.31Cr 2.94Cr 2.75Cr 2.51Cr 4.72Cr 318.77Cr 4.78Cr 33Cr 13Cr 162.34Cr 12Cr 12Cr 521.43Cr	22Cr 25Cr 3.24Cr 2.88Cr 2.69Cr 2.45Cr 4.62Cr 311.93Cr 4.68Cr 33Cr 13Cr 158.86Cr 12Cr 12Cr 510.25Cr